MRK
The smart-money shopping cart got heavier
Merck keeps collecting little confidence boosts, and this one came from Norris Perne & French LLP MI, which added 28,635 shares in the quarter and now owns 252,162 shares worth roughly $26.54 million. In portfolio-land, that’s not a casual “add to cart.” That’s a meaningful bet.
Why investors should care
The stock doesn’t move just because one fund bought more shares — Wall Street is not a seismograph for one portfolio manager. But these filings matter because they hint at where professional money thinks the better risk/reward is hiding.
And Merck already has a few things going for it:
- it beat quarterly EPS estimates
- it guided FY2026 EPS to $5.00–$5.15
- the FDA granted Priority Review for ifinatamab deruxtecan in extensive-stage small cell lung cancer
That’s a pretty decent cocktail of “the business is still working” and “the pipeline might not be decorative after all.”
The bigger vibe check
Analysts are also leaning a bit more upbeat, with recent target hikes helping push Merck toward a Moderate Buy consensus and an average target near $128.47. So while this specific filing isn’t a blockbuster on its own, it fits the broader story: Merck is starting to look like the kind of defensive giant people want to own when they’d rather not babysit a drama-fueled biotech.
Big picture: this isn’t the kind of headline that screams in all caps, but it’s another breadcrumb that says institutional investors are still willing to keep Merck on the menu.